Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

Phase 4TerminatedNCT01698944

Novo Nordisk A/S7 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Growth Hormone Disorder Adult Growth Hormone Deficiency

Interventions

somatropinDRUG

Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily

Eligibility

Sex: ALLMin age: 12 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult growth hormone deficiency * At least 2 years without growth hormone treatment Exclusion Criteria: * Supine blood pressure above 160 mmHg systolic or above 100 mmHg diastolic * Pregnancy

Locations (1)

Novo Nordisk Investigational Site

Athens, Greece

Outcomes

Primary Outcomes

Left Ventricular systolic function

Left Ventricular diastolic function

Secondary Outcomes

Body composition

Fasting glucose

HbA1c (glycosylated haemoglobin)

Oral glucose tolerance test (OGTT)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.